Skip to main content
Top
Published in: Drug Safety 8/2001

01-07-2001 | Leading Article

Is Gender a Risk Factor for Adverse Drug Reactions?

The Example of Drug-Induced Long QT Syndrome

Authors: Dr Milou-Daniel Drici, Nathalie Clément

Published in: Drug Safety | Issue 8/2001

Login to get access

Abstract

Drug-induced torsade de pointes is a rare life-threatening adverse drug reaction (ADR) which is strongly influenced by gender. Drugs that prolong cardiac repolarisation include antiarrhythmics, gastrokinetics, antipsychotics, antihistamines and antibacterials. Such drugs share the potential to block cardiac voltagegated potassium channels, particularly the rapid component (IKr) of the delayed rectifier potassium current (IK). By doing so, such drugs usually, but not always, prolong the QT interval. Even if the electrocardiographic signs are subdued, the underlying blockade of IKr current may precipitate the occurrence of arrhythmia.
Women are perceived to be more prone to ADRs than men. Such a propensity may result from gender-associated differences in drug exposure, in the number of drugs prescribed (polypharmacy), in drug pharmacology, as well as from possible differences in the way the adverse event is perceived. A prolonged QT interval on the electrocardiogram (time that elapses from the onset of the cardiac ventricular depolarisation to the completion of its repolarisation) is associated with the occurrence of torsade de pointes and related ventricular arrhythmias. The QT interval is influenced by heart rate, autonomic nervous system, electrolyte disturbances and above all, drugs that block potassium channels.
Two-thirds of the cases of drug-induced torsade de pointes occur in women. Therefore, this adverse effect represents a perfect example of gender differences impairing women’s health. Clinical and experimental studies show that female gender is associated with a longer corrected QT interval at baseline and a greater response to drugs that block IKr, both of which facilitate the emergence of arrhythmia. This results most likely from a specific regulation of ionic channel expression (potassium, calcium, etc) by sex steroids, even though nongenomic effects may play a role as well. Estrogens facilitate bradycardia-induced prolongation of the QT interval and the emergence of arrhythmia whereas androgens shorten the QT interval and blunt the QT response to drugs. Hence, underlying genetic defects of potassium channels that may be asymptomatic in normal conditions, may precipitate drug-induced arrhythmia in women more frequently than in men. Even in the presence of a drug that mildly blocks IKr and seldom prolongs the QT interval, women are still more prone to drug-induced torsade de pointes, due to their reduced cardiac “repolarisation reserve’. This is an important aspect of IKr blockade to be aware of during the development of new drugs.
Literature
1.
go back to reference Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease: a review. Ann N Y Acad Sci 1990; 592 193–203; 57-62PubMedCrossRef Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease: a review. Ann N Y Acad Sci 1990; 592 193–203; 57-62PubMedCrossRef
2.
go back to reference Rosengren A, Dotevall A, Eriksson H, et al. Optimal risk factors in the population: prognosis, prevalence, and secular trends. Data from Goteborg population studies. Eur Heart J 2001; 22(2): 136–44PubMedCrossRef Rosengren A, Dotevall A, Eriksson H, et al. Optimal risk factors in the population: prognosis, prevalence, and secular trends. Data from Goteborg population studies. Eur Heart J 2001; 22(2): 136–44PubMedCrossRef
3.
go back to reference Guentert TW, Banken L, Hilton S, et al. Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol 1995; 154 Suppl. 2: 84S–94SPubMedCrossRef Guentert TW, Banken L, Hilton S, et al. Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol 1995; 154 Suppl. 2: 84S–94SPubMedCrossRef
4.
go back to reference Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101(1): 34–40PubMedCrossRef Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101(1): 34–40PubMedCrossRef
5.
go back to reference Tran C, Knowles SR, Liu BA, et al. Gender differences in adverse drug reactions. J Clin Pharmacol 1998; 38(11): 1003–9PubMedCrossRef Tran C, Knowles SR, Liu BA, et al. Gender differences in adverse drug reactions. J Clin Pharmacol 1998; 38(11): 1003–9PubMedCrossRef
6.
go back to reference Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49(2): 158–67PubMedCrossRef Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49(2): 158–67PubMedCrossRef
7.
go back to reference Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50(2): 222–39PubMedCrossRef Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50(2): 222–39PubMedCrossRef
8.
go back to reference Strohle A. Increased response to a putative panicogenic nocebo administration in female patients with panic disorder. J Psychiatr Res 2000; 34(6): 439–42PubMedCrossRef Strohle A. Increased response to a putative panicogenic nocebo administration in female patients with panic disorder. J Psychiatr Res 2000; 34(6): 439–42PubMedCrossRef
9.
go back to reference Saxon L, Hiltunen AJ, Hjemdahl P, et al. Gender-related differences in response to placebo in benzodiazepine withdrawal: a single-blind pilot study. Psychopharmacology (Berl) 2001; 153(2): 231–7CrossRef Saxon L, Hiltunen AJ, Hjemdahl P, et al. Gender-related differences in response to placebo in benzodiazepine withdrawal: a single-blind pilot study. Psychopharmacology (Berl) 2001; 153(2): 231–7CrossRef
10.
go back to reference Hulst LK, Fleishaker JC, Peters GR, et al. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994; 55(4): 378–84PubMedCrossRef Hulst LK, Fleishaker JC, Peters GR, et al. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994; 55(4): 378–84PubMedCrossRef
11.
go back to reference Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66(6): 594–601PubMed Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66(6): 594–601PubMed
12.
go back to reference Drici MD, Raybaud F, De Lunardo C, et al. Influence of the behaviour pattern on the nocebo response of healthy volunteers. Br J Clin Pharmacol 1995; 39(2): 204–6PubMedCrossRef Drici MD, Raybaud F, De Lunardo C, et al. Influence of the behaviour pattern on the nocebo response of healthy volunteers. Br J Clin Pharmacol 1995; 39(2): 204–6PubMedCrossRef
13.
go back to reference Edmeads JG, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist: international clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia 1997; 17Suppl. 18: 41–52PubMed Edmeads JG, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist: international clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia 1997; 17Suppl. 18: 41–52PubMed
14.
go back to reference Casper RC, Tollefson GD, Nilsson ME. No gender differences in placebo responses of patients with major depressive disorder. Biol Psychiatry 2001; 49(2): 158–60PubMedCrossRef Casper RC, Tollefson GD, Nilsson ME. No gender differences in placebo responses of patients with major depressive disorder. Biol Psychiatry 2001; 49(2): 158–60PubMedCrossRef
15.
go back to reference Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur Vaiss 1966; 59 263–72PubMed Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur Vaiss 1966; 59 263–72PubMed
16.
go back to reference Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. Drugs 1994; 47(1): 51–65PubMedCrossRef Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. Drugs 1994; 47(1): 51–65PubMedCrossRef
17.
18.
go back to reference Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21(5): 1029–34PubMedCrossRef Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21(5): 1029–34PubMedCrossRef
19.
go back to reference Bazett H. An analysis of the time relationship of electrocardiograms. Heart 1920; 7: 353–70 Bazett H. An analysis of the time relationship of electrocardiograms. Heart 1920; 7: 353–70
20.
go back to reference Glancy JM, Garratt CJ, Woods KL, et al. QT dispersion and mortality after myocardial infarction. Lancet 1995; 345(8955): 945–8PubMedCrossRef Glancy JM, Garratt CJ, Woods KL, et al. QT dispersion and mortality after myocardial infarction. Lancet 1995; 345(8955): 945–8PubMedCrossRef
21.
go back to reference Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63(6): 342–4PubMedCrossRef Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63(6): 342–4PubMedCrossRef
22.
go back to reference Hii JT, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86(5): 1376–82PubMedCrossRef Hii JT, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86(5): 1376–82PubMedCrossRef
23.
go back to reference Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr: implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93(3): 407–11PubMedCrossRef Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr: implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93(3): 407–11PubMedCrossRef
24.
go back to reference Coumel P, Maison-Blanche P. Physiology of QT interval dynamicity. Cardiac Electrophysiol Rev 1997; 1: 364–7CrossRef Coumel P, Maison-Blanche P. Physiology of QT interval dynamicity. Cardiac Electrophysiol Rev 1997; 1: 364–7CrossRef
25.
go back to reference Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J 1999; 20(3): 174–95PubMedCrossRef Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J 1999; 20(3): 174–95PubMedCrossRef
26.
go back to reference Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11(6): 691–6PubMedCrossRef Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11(6): 691–6PubMedCrossRef
27.
go back to reference Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984; 35(6): 792–7PubMedCrossRef Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984; 35(6): 792–7PubMedCrossRef
28.
go back to reference Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996; 94(6): 1471–4PubMedCrossRef Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996; 94(6): 1471–4PubMedCrossRef
29.
go back to reference Liu XK, Katchman A, Drici MD, et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 1998; 285(2): 672–9PubMed Liu XK, Katchman A, Drici MD, et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 1998; 285(2): 672–9PubMed
30.
go back to reference Hara M, Danilo PJ, Rosen MR. Effects of gonadal steroids on ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther 1998; 285(3): 1068–72PubMed Hara M, Danilo PJ, Rosen MR. Effects of gonadal steroids on ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther 1998; 285(3): 1068–72PubMed
31.
go back to reference Chen YJ, Lee SH, Hsieh MH, et al. Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. J Cardiovasc Electrophysiol 1999; 10(4): 587–98PubMedCrossRef Chen YJ, Lee SH, Hsieh MH, et al. Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. J Cardiovasc Electrophysiol 1999; 10(4): 587–98PubMedCrossRef
32.
go back to reference Drici MD, Knollmann BC, Wang WX, et al. Cardiac actions of erythromycin: influence of female sex. JAMA 1998; 280(20): 1774–6PubMedCrossRef Drici MD, Knollmann BC, Wang WX, et al. Cardiac actions of erythromycin: influence of female sex. JAMA 1998; 280(20): 1774–6PubMedCrossRef
33.
go back to reference Benton RE, Sale M, Flockhart DA, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67(4): 413–8PubMedCrossRef Benton RE, Sale M, Flockhart DA, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67(4): 413–8PubMedCrossRef
34.
go back to reference Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97(2): 175–87PubMedCrossRef Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97(2): 175–87PubMedCrossRef
35.
go back to reference Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97(19): 10613–8PubMedCrossRef Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97(19): 10613–8PubMedCrossRef
36.
go back to reference Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99(4): 529–33PubMedCrossRef Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99(4): 529–33PubMedCrossRef
37.
go back to reference Merri M, Benhorin J, Alberti M, et al. Electrocardiographic quantitation of ventricular repolarization. Circulation 1989; 80(5): 1301–8PubMedCrossRef Merri M, Benhorin J, Alberti M, et al. Electrocardiographic quantitation of ventricular repolarization. Circulation 1989; 80(5): 1301–8PubMedCrossRef
38.
go back to reference Morcet JF, Safar M, Thomas F, et al. Associations between heart rate and other risk factors in a large French population. J Hypertens 1999; 17(12 Pt 1): 1671–6PubMedCrossRef Morcet JF, Safar M, Thomas F, et al. Associations between heart rate and other risk factors in a large French population. J Hypertens 1999; 17(12 Pt 1): 1671–6PubMedCrossRef
39.
go back to reference Stramba-Badiale M, Spagnolo D, Bosi G, et al. Are gender differences in QTc present at birth? MISNES Investigators. Multicenter Italian Study on Neonatal Electrocardiography and Sudden Infant Death Syndrome. Am J Cardiol 1995; 75(17): 1277–8PubMedCrossRef Stramba-Badiale M, Spagnolo D, Bosi G, et al. Are gender differences in QTc present at birth? MISNES Investigators. Multicenter Italian Study on Neonatal Electrocardiography and Sudden Infant Death Syndrome. Am J Cardiol 1995; 75(17): 1277–8PubMedCrossRef
40.
go back to reference Nagy E, Orvos H, Bardos G, et al. Gender-related heart rate differences in human neonates. Pediatr Res 2000; 47(6): 778–80PubMedCrossRef Nagy E, Orvos H, Bardos G, et al. Gender-related heart rate differences in human neonates. Pediatr Res 2000; 47(6): 778–80PubMedCrossRef
41.
go back to reference Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8(7): 690–5PubMed Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8(7): 690–5PubMed
42.
go back to reference Kassotis J, Costeas C, Bedi AK, et al. Effects of aging and gender on QT dispersion in an overtly healthy population. Pacing Clin Electrophysiol 2000; 23(7): 1121–6PubMedCrossRef Kassotis J, Costeas C, Bedi AK, et al. Effects of aging and gender on QT dispersion in an overtly healthy population. Pacing Clin Electrophysiol 2000; 23(7): 1121–6PubMedCrossRef
43.
go back to reference Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94(10): 2535–41PubMedCrossRef Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94(10): 2535–41PubMedCrossRef
44.
go back to reference Pratt CM, Camm AJ, Cooper W, et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998; 81(7): 869–76PubMedCrossRef Pratt CM, Camm AJ, Cooper W, et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998; 81(7): 869–76PubMedCrossRef
45.
go back to reference Lehmann MH, Hardy S, Archibald D, et al. JTc prolongation with d,l-sotalol in women versus men. Am J Cardiol 1999; 83(3): 354–9PubMedCrossRef Lehmann MH, Hardy S, Archibald D, et al. JTc prolongation with d,l-sotalol in women versus men. Am J Cardiol 1999; 83(3): 354–9PubMedCrossRef
46.
go back to reference Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 1998; 7(5): 547–57PubMedCrossRef Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 1998; 7(5): 547–57PubMedCrossRef
47.
go back to reference Cramer G. Early and late results of conversion of atrial fibrillation with quinidine. A clinical and hemodynamic study. Acta Med Scand Suppl. 1968; 490: 5–102PubMed Cramer G. Early and late results of conversion of atrial fibrillation with quinidine. A clinical and hemodynamic study. Acta Med Scand Suppl. 1968; 490: 5–102PubMed
48.
go back to reference Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270(21): 2590–7PubMedCrossRef Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270(21): 2590–7PubMedCrossRef
49.
go back to reference Prystowsky EN, Benson DW, Fuster V, et al. Management of patientswith atrial fibrillation. Astatement for healthcare professionals. From the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93(6): 1262–77PubMedCrossRef Prystowsky EN, Benson DW, Fuster V, et al. Management of patientswith atrial fibrillation. Astatement for healthcare professionals. From the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93(6): 1262–77PubMedCrossRef
51.
go back to reference Wesche DL, Schuster BG, Wang WX, et al. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2000; 67(5): 521–9PubMedCrossRef Wesche DL, Schuster BG, Wang WX, et al. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2000; 67(5): 521–9PubMedCrossRef
52.
go back to reference Woosley RL. Georgetown University Medical Center. A representative list of drugs that prolong the QT interval and/or induce torsade de pointes with substantial evidence for a gender difference (when mentioned). 2001. Available from URL: http://www.torsades.org. [Accessed Oct 2000] Woosley RL. Georgetown University Medical Center. A representative list of drugs that prolong the QT interval and/or induce torsade de pointes with substantial evidence for a gender difference (when mentioned). 2001. Available from URL: http://​www.​torsades.​org. [Accessed Oct 2000]
53.
go back to reference Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 1993; 25(2): 103–14PubMedCrossRef Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 1993; 25(2): 103–14PubMedCrossRef
54.
go back to reference Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55(5): 509–17PubMedCrossRef Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55(5): 509–17PubMedCrossRef
55.
go back to reference Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103(3): 375–80PubMedCrossRef Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103(3): 375–80PubMedCrossRef
56.
go back to reference Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001; 21(1): 14–20PubMedCrossRef Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001; 21(1): 14–20PubMedCrossRef
57.
go back to reference Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 1997; 29(1): 93–9PubMedCrossRef Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 1997; 29(1): 93–9PubMedCrossRef
58.
go back to reference Hashiba K. Sex differences in phenotypic manifestation and gene transmission in the Romano-Ward syndrome. Ann NY Acad Sci 1992; 644 142–56PubMedCrossRef Hashiba K. Sex differences in phenotypic manifestation and gene transmission in the Romano-Ward syndrome. Ann NY Acad Sci 1992; 644 142–56PubMedCrossRef
59.
go back to reference Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97(22): 2237–44PubMedCrossRef Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97(22): 2237–44PubMedCrossRef
60.
go back to reference Larsen JA, Tung RH, Sadananda R, et al. Effects of hormone replacement therapy on QT interval. Am J Cardiol 1998; 82(8): 993–5PubMedCrossRef Larsen JA, Tung RH, Sadananda R, et al. Effects of hormone replacement therapy on QT interval. Am J Cardiol 1998; 82(8): 993–5PubMedCrossRef
61.
go back to reference Rosano GM, Leonardo F, Sarrel PM, et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet 1996; 347(9004): 786–8PubMedCrossRef Rosano GM, Leonardo F, Sarrel PM, et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet 1996; 347(9004): 786–8PubMedCrossRef
62.
go back to reference Drici MD, Ducic I, Morad M, et al. Gender differences in cardiac repolarization depends on IK1 and ItoK+ channel currents in the rabbit. Circulation 1996; 94(8): I–473 Drici MD, Ducic I, Morad M, et al. Gender differences in cardiac repolarization depends on IK1 and ItoK+ channel currents in the rabbit. Circulation 1996; 94(8): I–473
63.
go back to reference Knollmann BC, Ender SI, Franz MR, et al. Acute effects of 17beta-estradiol and dihydrotestosterone on action potential duration and QT-interval in isolated rabbit hearts. J Invest Med 1996; 44(3): 209A Knollmann BC, Ender SI, Franz MR, et al. Acute effects of 17beta-estradiol and dihydrotestosterone on action potential duration and QT-interval in isolated rabbit hearts. J Invest Med 1996; 44(3): 209A
64.
go back to reference Pragnell M, Snay KJ, Trimmer JS, et al. Estrogen induction of a small, putative K+ channel mRNA in rat uterus. Neuron 1990; 4 807–12PubMedCrossRef Pragnell M, Snay KJ, Trimmer JS, et al. Estrogen induction of a small, putative K+ channel mRNA in rat uterus. Neuron 1990; 4 807–12PubMedCrossRef
65.
go back to reference Stumpf WE, Sar M. Autoradiographic localization of estrogen, androgen, progestin and glucocorticosteroid in ‘target tissues’ and b‘non target tissues’. In: Pasqualini J, editor. Receptors and mechanism of action of steroid hormones. New York (NY): Marcel Dekker, 1976: 41–84 Stumpf WE, Sar M. Autoradiographic localization of estrogen, androgen, progestin and glucocorticosteroid in ‘target tissues’ and b‘non target tissues’. In: Pasqualini J, editor. Receptors and mechanism of action of steroid hormones. New York (NY): Marcel Dekker, 1976: 41–84
66.
go back to reference Waldegger S, Lang U, Herzer T, et al. Inhibition of minK protein induced K+ channels in Xenopus oocytes by estrogens. Naunyn Schmiedebergs Arch Pharmakol 1996; 354(6): 698–702CrossRef Waldegger S, Lang U, Herzer T, et al. Inhibition of minK protein induced K+ channels in Xenopus oocytes by estrogens. Naunyn Schmiedebergs Arch Pharmakol 1996; 354(6): 698–702CrossRef
67.
go back to reference Moller RA, Datta S, Strichartz GR. Beta-estradiol acutely potentiates the depression of cardiac excitability by lidocaine and bupivacaine. J Cardiovasc Pharmacol 1999; 34(5): 718–27PubMedCrossRef Moller RA, Datta S, Strichartz GR. Beta-estradiol acutely potentiates the depression of cardiac excitability by lidocaine and bupivacaine. J Cardiovasc Pharmacol 1999; 34(5): 718–27PubMedCrossRef
68.
go back to reference Liu XK, Katchman A, Ebert SN, et al. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 1998; 287(3): 877–83PubMed Liu XK, Katchman A, Ebert SN, et al. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 1998; 287(3): 877–83PubMed
69.
go back to reference Moller RA, Datta S, Fox J, et al. Effects of progesterone on the cardiac electrophysiologic action of bupivacaine and lidocaine. Anesthesiology 1992; 76(4): 604–8PubMedCrossRef Moller RA, Datta S, Fox J, et al. Effects of progesterone on the cardiac electrophysiologic action of bupivacaine and lidocaine. Anesthesiology 1992; 76(4): 604–8PubMedCrossRef
70.
go back to reference Song J, Standley PR, Zhang F, et al. Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther 1996; 277(3): 1444–53PubMed Song J, Standley PR, Zhang F, et al. Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther 1996; 277(3): 1444–53PubMed
71.
go back to reference Ruehlmann DO, Steinert JR, Valverde MA, et al. Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells. FASEB J 1998; 12(7): 613–9PubMed Ruehlmann DO, Steinert JR, Valverde MA, et al. Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells. FASEB J 1998; 12(7): 613–9PubMed
72.
go back to reference Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72(6): 17B–22BPubMedCrossRef Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72(6): 17B–22BPubMedCrossRef
73.
go back to reference Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995; 92(12): 3381–6PubMedCrossRef Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995; 92(12): 3381–6PubMedCrossRef
74.
go back to reference Hirao H, Shimizu W, Kurita T, et al. Frequency-dependent electrophysiologic properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol 1996; 28(5): 1269–77PubMedCrossRef Hirao H, Shimizu W, Kurita T, et al. Frequency-dependent electrophysiologic properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol 1996; 28(5): 1269–77PubMedCrossRef
75.
go back to reference Krahn AD, Klein GJ, Yee R. Hysteresis of the RT interval with exercise: a new marker for the long-QT syndrome? Circulation 1997; 96(5): 1551–6PubMedCrossRef Krahn AD, Klein GJ, Yee R. Hysteresis of the RT interval with exercise: a new marker for the long-QT syndrome? Circulation 1997; 96(5): 1551–6PubMedCrossRef
76.
go back to reference Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. Am J Cardiol 1991; 68(5): 498–503PubMedCrossRef Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. Am J Cardiol 1991; 68(5): 498–503PubMedCrossRef
77.
go back to reference Demolis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94(7): 1592–9PubMedCrossRef Demolis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94(7): 1592–9PubMedCrossRef
78.
go back to reference Stark G, Schwarzl I, Heiden U, et al. Magnesium abolishes inadequate kinetics of frequency adaptation of the Q-aT interval in the presence of sotalol. Cardiovasc Res 1997; 35(1): 43–5PubMedCrossRef Stark G, Schwarzl I, Heiden U, et al. Magnesium abolishes inadequate kinetics of frequency adaptation of the Q-aT interval in the presence of sotalol. Cardiovasc Res 1997; 35(1): 43–5PubMedCrossRef
79.
go back to reference Kliegfield P, Lax KG, Okin PM. QT interval-heart rate relation during exercise in normal men and women: definition by linear regression analysis. J Am Coll Cardiol 1996; 28(6): 1547–55CrossRef Kliegfield P, Lax KG, Okin PM. QT interval-heart rate relation during exercise in normal men and women: definition by linear regression analysis. J Am Coll Cardiol 1996; 28(6): 1547–55CrossRef
80.
go back to reference Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 1997; 18(6): 1000–6PubMedCrossRef Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 1997; 18(6): 1000–6PubMedCrossRef
81.
go back to reference Drici MD, Arrighi I, Chouabe C, et al. Involvment of IsK associated K+ channel in heart rate control of repolarization in a murine engineered model of Jervell and Lange-Nielsen syndrome. Circ Res 1998; 83: 95–102PubMedCrossRef Drici MD, Arrighi I, Chouabe C, et al. Involvment of IsK associated K+ channel in heart rate control of repolarization in a murine engineered model of Jervell and Lange-Nielsen syndrome. Circ Res 1998; 83: 95–102PubMedCrossRef
82.
go back to reference Liu XK, Wang W, Ebert SN, et al. Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol 1999; 34(2): 287–94PubMedCrossRef Liu XK, Wang W, Ebert SN, et al. Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol 1999; 34(2): 287–94PubMedCrossRef
83.
go back to reference Larsen JA, Kadish AH. Effects of gender on cardiac arrhythmias. J Cardiovasc Electrophysiol 1998; 9(6): 655–64PubMedCrossRef Larsen JA, Kadish AH. Effects of gender on cardiac arrhythmias. J Cardiovasc Electrophysiol 1998; 9(6): 655–64PubMedCrossRef
84.
go back to reference Shipley RA, Hallaran WR. The four lead electrocardiogram in two hundred normal men and women. Am Heart J 1936; 11 325–45CrossRef Shipley RA, Hallaran WR. The four lead electrocardiogram in two hundred normal men and women. Am Heart J 1936; 11 325–45CrossRef
Metadata
Title
Is Gender a Risk Factor for Adverse Drug Reactions?
The Example of Drug-Induced Long QT Syndrome
Authors
Dr Milou-Daniel Drici
Nathalie Clément
Publication date
01-07-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124080-00002

Other articles of this Issue 8/2001

Drug Safety 8/2001 Go to the issue

Leading Article

Thiomersal in Vaccines